Menu
  • The Barrow Neuroplex
  • Find a Doctor
  • International Patients
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • News & Stories
  • Transfer a Patient
  • 233AS101 (SOD1)

    Enrollment Information

    Call (602) 406-6606 or E-Mail [email protected]

    The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of BIIB067 in adults with ALS and confirmed superoxide dismutase 1 (SOD1) mutation. BIIB067 will be administered via lumbar punctures over a 24-week treatment period (i.e. 3 loading doses administered approximately once every 2 weeks, followed by 5 maintenance doses administered approximately once every 4 weeks). Overall, participants will be in the research study for about 32 weeks.

    Principal Investigator: Shafeeq Ladha, MD

     

    About Barrow Neurological Institute
    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premier destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.